Nuvectis says China grants breakthrough therapy tag to NXP200 for BRAF V600-mutant high-grade gliomaPUBT·Sep 24, 2026 at 12:04 PMNVCT-7.78%002653-2.89%
Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 millionPUBT·Aug 4, 2026 at 12:08 PMNVCT-7.78%002653-2.89%
Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsPUBT·Jul 23, 2026 at 11:32 AMNVCT-7.78%002653-2.89%
China's Haisco Gets China’s Nod for Rare Blood Disorder DrugYicai·Jul 23, 2026 at 11:27 AM002653-2.89%NVCT-7.78%
02:08 ETHaisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNHprnewswire·Jul 23, 2026 at 06:10 AM002653-2.89%
Haisco and Nuvectis sign licensing deal for two drugsPharmaceutical Technology·Jun 24, 2026 at 08:10 AMNVCT-7.78%002653-2.89%
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement IndicationsUnusual Whales·Jun 23, 2026 at 01:20 PM002653-2.89%NVCT-7.78%
Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trendingbenzinga_article·Jun 23, 2026 at 06:30 AMNVCT-7.78%002653-2.89%
Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLArttnews·Jun 23, 2026 at 03:15 AMAZTR+113.99%FTH-1.46%
Nuvectis licenses ex-China rights to Haisco’s NXP100, NXP200 in deal worth up to USD 1.42 billionPUBT·Jun 22, 2026 at 11:30 AMNVCT-7.78%
Nuvectis Pharma shares are trading higher after the company announced a strategic portfolio expansion with Haisco Pharmaceutical Group. Also, HC Wainwright & Co raised its price target on the stock from $13 to $39.benzinga_article·Jun 22, 2026 at 05:38 PMNVCT-7.78%002653-2.89%
